Molecular and clinical characterization of ETNK1-mutated myeloid neoplasms: the Mayo Clinic experience
Blood Adv
.
2024 Sep 24;8(18):4807-4811.
doi: 10.1182/bloodadvances.2024013255.
Authors
Steven Tessier
1
,
Rong He
2
,
Patricia Greipp
2
,
David Viswanatha
2
,
Kurt Bessonen
2
,
Terra Lasho
3
,
James Foran
4
,
Cecilia Arana-Yi
5
,
Naseema Gangat
3
,
Ayalew Tefferi
3
,
Mithun Shah
3
,
Hassan Alkhateeb
3
,
Shujun Liu
6
,
Animesh Pardanani
3
,
Mrinal Patnaik
3
,
Aref Al-Kali
3
Affiliations
1
Department of Internal Medicine, Mayo Clinic School of Graduate Medical Education, Rochester, MN.
2
Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
3
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
4
Division of Hematology, Department of Medicine, Mayo Clinic, Jacksonville, FL.
5
Division of Hematology, Department of Medicine, Mayo Clinic, Phoenix, AZ.
6
Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH.
PMID:
39042872
PMCID:
PMC11415849
DOI:
10.1182/bloodadvances.2024013255
No abstract available
MeSH terms
Adult
Aged
Female
Humans
Male
Middle Aged
Mutation*
Myeloproliferative Disorders* / diagnosis
Myeloproliferative Disorders* / genetics
Substances
ethanolamine kinase